Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical Benefits Scheme, arguing funding the treatment will reduce a costly ...

Speaking at the reopening of the Thailand office of Novo Nordisk, a leading global healthcare company, Mr Annan highlighted how the company is driven not only by pharmaceutical excellence but also ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

Novo Nordisk’s annual results are out and they show the Danish pharmaceutical juggernaut earnt 290.4 billion Danish kroner last year (A$64 billion) — up 25%. Novo Nordisk boasts 45 million ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management ...